YU-CHEN SYSTEM TECHNOLOGY CORP.
Update：2025/01/01
Industries
Main Industry
Manufacturing
Main Product/Service
From human-heavy workflows to fully AI-driven autonomous experimentation. The system rapidly builds a scalable pipeline for a wide range of organ-on-chip applications, supporting continuous feedback and real-time adjustments from preclinical research through to clinical translation. It accelerates decision-making and improves the precision of therapeutic development.
1
2
3
How we can help
Design House
Build automated organ-on-chip pipelines with large language models. Design House provides AI modules that drive every stage of experimentation, from protocol generation to real-time monitoring and data analysis. Continuously enriched by internal and external datasets, the system evolves with each use, ensuring that every experiment reflects the most current and relevant scientific knowledge.
Design House
Organ Modeling
Standardized workflows enable the construction of complex, multi-tissue models that replicate organ-level functions. The system supports large-scale testing and provides insights into drug Mechanism of Action (MOA).
Organ Modeling
Decision Making
Support faster and more confident decisions. By analyzing dynamic biological responses across physiologically relevant models, our platform empowers critical decision-making in:
‧ Drug screening and selection
‧ Preclinical toxicity prediction
‧ Efficacy testing of approved drugs
1
2
3
How we can help
Design House
Build automated organ-on-chip pipelines with large language models. Design House provides AI modules that drive every stage of experimentation, from protocol generation to real-time monitoring and data analysis. Continuously enriched by internal and external datasets, the system evolves with each use, ensuring that every experiment reflects the most current and relevant scientific knowledge.
Design House
Organ Modeling
Standardized workflows enable the construction of complex, multi-tissue models that replicate organ-level functions. The system supports large-scale testing and provides insights into drug Mechanism of Action (MOA).
Organ Modeling
Decision Making
Support faster and more confident decisions. By analyzing dynamic biological responses across physiologically relevant models, our platform empowers critical decision-making in:
‧ Drug screening and selection
‧ Preclinical toxicity prediction
‧ Efficacy testing of approved drugs
Founded Year
2010
Unified Business No.
53161763
Status
Active
Number of Employees
404
Total Paid-in
Capital
186,864,000 (NT$)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Location of Company
Taiwan
, Hsinchu City
Exit Status
Emerging Stock Exchange(2025)
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Anivance AI is bridging Taiwan’s world-class semiconductor and manufacturing expertise with AI and life sciences, creating a new era of intelligent drug discovery. By integrating AI-powered organ-on-chip technology with automated high-throughput research, we provide pharmaceutical companies with a scalable, self-optimizing platform that accelerates preclinical testing and delivers breakthrough insights. Our platform is continuously learning and adapting, optimizing experiment design, mechanistic analysis (MOA), and real-time data interpretation.
By embedding AI agents into automated research workflows, we help pharmaceutical companies make faster, smarter, and more data-driven decisions, significantly reducing preclinical failure rates and improving R&D efficiency.
By embedding AI agents into automated research workflows, we help pharmaceutical companies make faster, smarter, and more data-driven decisions, significantly reducing preclinical failure rates and improving R&D efficiency.
